Released Nov 7, 2016, after the close
10-Q filed Nov 7, 2016, 38 days after period end · 0001193125-16-761702
Q3 2016 · 10-Q
Revenue$48.00K$48.00K −36.0% vs Q3 2015−18.6% vs Q2 2016
Net Income-$25.43M-$25.43M N/M vs Q3 2015N/M vs Q2 2016
EPS Diluted-$0.69-$0.69 N/M vs Q3 2015N/M vs Q2 2016
Operating Income-$25,742,000N/M
Operating Cash Flowderived-$20,334,000N/M
Free Cash Flowderived-$20,334,000N/M
Margins · derived
Operating margin-53629.2%−12815.8 pt vs Q3 2015
Net margin-52968.8%−12471.4 pt vs Q3 2015
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2016 | Q3 2015 | Q3 2014 | Q3 2013 |
|---|---|---|---|---|
| Revenue | $48.00K | $75.00K | $21.00K | $0.00 |
| Net Income | -$25.43M | -$30.37M | -$19.72M | — |
| EPS Diluted | -$0.69 | -$0.85 | -$0.61 | -$3.66 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR